GLP-1 Receptor Agonists: A Game-Changer for Type 2 Diabetes, Obesity, and Cardiometabolic Health APRNs treating patients with type 2 diabetes, obesity, and cardiometabolic risk factors are seeing a significant shift in frontline pharmacologic care
Calorie counters bolt on GLP-1 features, but they rarely handle injection site rotation or dose escalation well
To prospectively test the ability of this model to design new peptides with specific activity, we used a simple optimization strategy to design 15 peptides, five in each of three different activity profiles: selective potency at GCGR, selective potency at GLP-1R or high-potency at both receptors
Which GLP-1 medications are included in the Medicare Bridge program
That hormone also tells the liver to make new sugar, which is kept in check by GIP and GLP-1 activity, preventing blood sugar spikes